Mechanism

Endpoint	TE [95% CI]	p val	n	k
Mortality (early)	1.04 [0.28 3.85]	p=1.00	182	5	Arneson, Common, Elsharawy, Schulman, Kakkar (streptokinase),
Pulmonary embolism (early)	0.60 [0.12 3.10]	p=1.00	132	4	Arneson, Elsharawy, Schulman, Kakkar (streptokinase),
Bleeding (early)	1.52 [0.67 3.45]	p=1.00	181	5	Arneson, Common, Elsharawy, Schulman, Kakkar (streptokinase),
Any improvement in venous patency (early)	12.15 [7.16 20.61]	p=0.04	141	4	Arneson, Common, Elsharawy, Kakkar (streptokinase),
Complete clot lysis (early)	3.03 [1.10 8.31]	p=0.04	129	4	Common, Elsharawy, Schulman, Kakkar (streptokinase),
Stroke/intracerebral bleeding (early)	1.27 [0.27 6.06]	p=1.00	215	6	Arneson, Common, Elsharawy, Schulman, Tsapogas, Kakkar (streptokinase),
Leg ulceration (late)	0.32 [0.03 3.56]	p=1.00	71	2	Arneson, Schulman,
Mortality (late)	1.33 [0.26 6.85]	p=1.00	42	1	Arneson,
Post-thrombotic syndrome (late)	0.47 [0.11 2.01]	p=1.00	35	1	Arneson,
Complete clot lysis (late)	3.77 [1.39 10.27]	p=0.04	123	4	Arneson, Common, Elsharawy, Schulman,
Normal venous function (late)	2.09 [0.68 6.45]	p=1.00	66	2	Elsharawy, Schulman,

Trial	Studied treatment	Control	Patients
Arneson, 1978	streptokinase 250,000 U loading IV, then 100,000 IU/hour IV 72-96 hours	heparin 15,000 IU IV bolus, 30,000 IU infusion IV 72-90 hours¢ßl	inpatients with venographically confirmed DVT extending proximally beyond the calf <5 days duration?
Common, 1976	hydrocortisone 100 mg IV then streptokinase IV 250,000 U over 30 minutes, then 100,000 U/hour titrated for 72 hours. Followed by IV heparin titrated over 7 days	IV heparin 150 U/kg loading dose then titrated for 10 days	patients with venographically confirmed DVT duration < 14 days
Elsharawy, 2002	catheter-directed thrombolysis with streptokinase using popliteal approach.	heparin IV bolus 5000 U, then adjusted continuous infusion. Warfarin begun the same evening	iliofemoral venous thrombosis confirmed by duplex or venography duration < 10 daysicatio
Schulman, 1986	streptokinase 50,000 IU IV over 15 minutes then 100,000 IU over 12 hours for up to 7 days, titrated. Given with 5000 IU heparin IV over 12 hours. Warfarin begun after streptokinase ended	heparin 5000 IUIVbolus then 30,000 IUper day, titrated for 7 days.Warfarin begun simultaneously	patients with venographically confirmed calf vein thrombosis of duration < 7 days.
Tsapogas, 1973	titrated dose of streptokinase IV into ankle veinmage/pj	heparin IV into affected limbitm	patients with DVT confirmed by venogram of duration < 5 days.
Kakkar (streptokinase), 1969	streptokinase 500,000 U IV over 30 minutes, 900,000 U every 6 hours for 5 days	heparin 10,000 U over 5 minutes, then 10,000 to 15,000 U every 6 hours for 5 dayslicatio	patients with venographically confirmed DVT of leg of duration < 4 days
Schweizer (systemic SK), 2000	Systemic streptokinase 3,000,000 U/day over 6 hours in conjunction with heparin for up to 7 days. Premedication: hydrocortisone 100 mg, ranitidine 50 mg, clemastine 2 mg	heparin IV, adjusted	patients with thrombosis of popliteal or more proximal veins confirmed by venogram at more than one level of duration < 9 days

T-pa

acute coronary syndrome, in all type of patients

all NS

T-pa

Major bleeding by 136% adverse event

short term death by 15% suggested

Long term death by 20% suggested

T-pa

all NS

T-pa

all NS

T-pa

Major bleeding by 18% suggested

Endpoint	TE [95% CI]	p val	I2	n	k
short term death	0.99 [0.94 1.03]	p=1.00	0	92583	10	GISSI II, International Study Group, ISIS III (SK/tPA), GUSTO tPA Hiv, Centre Illinois, Cherng, ECSG, PAIMS, TIMI-1, White,
reinfarction	0.46 [0.11 1.86]	p=1.00	0	122	1	Cherng,
Cardiovascular death	no data
Long term death	1.02 [0.96 1.07]	p=1.00	0	48294	2	International Study Group, ISIS III (SK/tPA),
Haemmorhagic stroke	no data
stroke (fatal and non fatal)	1.03 [0.88 1.20]	p=1.00	0	60797	4	GISSI II, International Study Group, ISIS III (SK/tPA), Cherng,
Major bleeding	0.82 [0.69 0.97]	p=0.04	0	61910	9	GISSI II, International Study Group, ISIS III (SK/tPA), Centre Illinois, Cherng, ECSG, PAIMS, TIMI-1, White,

Trial	Studied treatment	Control	Patients
GUSTO tPA Hiv, 1993	tPA accéléré (15 mg en bolus, puis 0.75 mg/kg en 30 min sans dépasser 50 mg puis 0.5 mg/kg en 60 min sans dépasser 35 mg) + héparine en IV (5000 U en bolus, 1000 U/h (de préférence 1200 U/h si > 80 kg), poursuivi au moins 48 h)	Streptokinase 1.5 MU en 60 min + héparine SC (12500 U 2 fois/j commencée 4h après thrombolytique) combiné à streptokinase (1.5 MU en 60 min) + héparine en IV (5000 U en bolus, puis 1000 U/h (1200 U/h si > 80 kg) poursuivi au moins 48 h)	Hommes et femmes
GISSI II, 1990	alteplase 100 mg infused intravenously over 3 h	streptokinase 1.5 MU infused intravenously over 30-60 min	patients with acute myocardial infarction within 6 h from onset of symptoms
International Study Group, 1990	tPA 100 mg en IV en 3 h (10 mg en bolus, puis 50 mg en 1 h, puis 20 mg/h pendant 2 h)	Streptokinase 1.5 MU en IV de 30 à 60 min	patients with suspected acute myocardial infarction of less than 6 h duration
ISIS III (SK/tPA), 1992	Streptokinase 1.5 MU en IV dune heure	tPA 0.04 MU/kg en IV en bolus d1 min, puis 0.36 MU/kg en 1 h, puis 0.067 MU/kg/h pendant 3 h	Hommes et femmes
Centre Illinois, 1993	t-PA 10 mg bolus, followed by 50 mg in the first hour, and 20 mg/hour for the next 2 hours	SK 375 000 IU bolus, followed by 1 125 000 IU/1 hage/pj	patients with AMI within 3h from onset of chest pain
Cherng, 1992	100 mg of rTPA over 3 hours (with early heparinization)	1,500,000 units of streptokinase over 1 hour	patients with acute myocardial infarction
ECSG, 1985	0.75 mg rt-PA/kg over 90 min	1 500 000 IU streptokinase over 60 min	patients with acute myocardial infarction of less than 6 h duration
PAIMS, 1989	intravenous cumulative dose of 100 mg rt-PA	.5 million units streptokinase	patients with acute myocardial infarction less than 3 h old
TIMI-1, 1987	rt-PA, 40, 20, and 20 mg in successive hours	SK 1.5 million units over 1 hr	patients with evolving acute myocardial infarction within 7 hr of the onset of symptoms
White, 1989	rt-PA 100 mg over three hours	streptokinase 1.5 million units over 30 minutes	patients with AMI

T-pa

all NS

T-pa

all NS

T-pa

acute myocardial infarction, in >6h from onset of symptoms

all NS

T-pa

cardiac arrest, in all type of patients

all NS

T-pa

Any improvement in venous patency (early) by 174% suggested

Endpoint	TE [95% CI]	p val	I2	n	k
Mortality (early)	no data
Pulmonary embolism (early)	no data
Bleeding (early)	2.12 [0.48 9.42]	p=1.00	0	148	2	Goldhaber (tPA alone), Turpie,
Any improvement in venous patency (early)	2.74 [1.20 6.27]	p=0.04	0	147	2	Goldhaber (tPA alone), Turpie,
Complete clot lysis (early)	no data
Stroke/intracerebral bleeding (early)	1.02 [0.02 52.88]	p=1.00	0	83	1	Turpie,
Leg ulceration (late)	no data
Mortality (late)	no data
Post-thrombotic syndrome (late)	no data
Complete clot lysis (late)	no data
Normal venous function (late)	no data

Trial	Studied treatment	Control	Patients
Goldhaber (tPA alone), 1990	tPA alone 0.05 mg/kg/hour IV over 24 hours, then heparin100U/kg bolus, then 1000 U/hour, adjusted	heparin alone 100 U/kg bolus, then 1000 U/hour	venographically documented DVT, in popliteal ormore proximal veins < 14 days duration
Schweizer (local tPA), 2000	local tPA 20 mg/day, over 4 hours via pedal vein for 4-7 days. IV heparin given simultaneously at 1000 IU/hour, adjusted	heparin IV, adjusted	patients with thrombosis of popliteal or more proximal veins confirmed by venogram at more than one level of duration < 9 days
Turpie, 1990	tPA + IV heparin	5000 U bolus then 30,000 U/24 hours, adjusted for 7-10 days (+placebo)	patients with venographically confirmed proximal DVT of lower limb of duration < 7 days
Verhaeghe (high dose), 1989	IV tPA 100 mg on day 1, 50 mg tPA on day 2. 10% of dose given as bolus; heparin 5000 U IV bolus then continuous infusion of 1000 U per hour for up to 72 hours	heparin 5000 U IV bolus then continuous infusion of 1000 U per hour for up to 72 hours (+placebo)	hospitalised patients with DVT of popliteal or more proximal veins of the lower leg, confirmed by venography of duration < 10 days.
Goldhaber (tPA+heparin), 1990	tPA 0.05 mg/kg/hour IV over 24 hours and heparin 100U/kg bolus, then 1000 U/hour, adjusted	heparin alone 100 U/kg bolus, then 1000 U/hour.	patients with venographically documented DVT, in popliteal ormore proximal veins < 14 days duration
Verhaeghe (low dose), 1989	IV tPA 50 mg on day 1, repeated on day 2. 10% of dose given as bolus; heparin 5000 U IV bolus then continuous infusion of 1000 U per hour for up to 72 hours	heparin 5000 U IV bolus then continuous infusion of 1000 U per hour for up to 72 hours (+placebo)	hospitalised patients with DVT of popliteal or more proximal veins of the lower leg, confirmed by venography of duration < 10 days.

Urokinase

acute myocardial infarction, in all type of patients

Urokinase

Urokinase

Urokinase

fibrinolysis